GI Dynamics has announced it has received conditional FDA approval to commence a pivotal clinical trial of the company’s EndoBarrier product, according to a news release. EndoBarrier is described as a ...
Investor Enquiries:United States:Robert Crane, Chief Financial Officer+1 (781) 357-3250orAustralia:Kim Jacobs, Inteq Limited+61 2 9231 3322orMedia Enquiries:North America/Europe:Dan Budwick, Pure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback